Comparative pharmacology of bipolar disorder and schizophrenia (Q33744368)

29 July 2017

1 reference

title

Comparative pharmacology of bipolar disorder and schizophrenia (English)

1 reference

29 July 2017

1 reference

1 reference

R M Post

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

published in

Schizophrenia Research

1 reference

29 July 2017

volume

39

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

153-8; discussion 163

1 reference

Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Induction of mania by risperidone resistant to mood stabilizers

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Mood Improvement Following Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation in Patients With Depression: A Placebo-Controlled Crossover Trial

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Transcranial magnetic stimulation in mania: a controlled study

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Lithium response in good prognosis schizophrenia.

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Pharmacologic studies of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Course of the Manic-Depressive Cycle and Changes Caused by Treatments

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

1 reference

7 January 2021

Mania associated with olanzapine

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Antiepileptic drug mechanisms of action

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Programmed cell death: implications for neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression.

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

In Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Clinical and biochemical effects of verapamil administration to schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century.

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Manic symptoms associated with initiation of risperidone

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Muscimol: GABA agonist therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

https://api.crossref.org/works/10.1016/S0920-9964(99)00115-2

7 January 2021

10.1016/S0920-9964(99)00115-2

Identifiers

DOI

1 reference

29 July 2017

1 reference